Literature DB >> 12516896

Epidural and intrathecal analgesia for cancer pain.

Divakara Kedlaya1, Lowell Reynolds, Steven Waldman.   

Abstract

The three-step analgesic ladder approach developed by the World Health Organization works well in treating the vast majority (70-90%) of patients suffering from pain related to cancer. In those patients who do not get pain relief by this three-step approach, intraspinal agents can be a fourth step in managing pain of malignant origin. Although morphine is the only opioid approved by the US Food and Drug Administration for intraspinal use, many different opioid analgesics are used intraspinally, including hydromorphone, fentanyl, sufentanil, meperidine and methadone in the treatment of cancer pain. Many non-opioid agents have also been used intraspinally either alone or in combination with opioids in the treatment of intractable cancer pain. This chapter summarizes the clinical use of these agents with some practical points.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12516896     DOI: 10.1053/bean.2002.0253

Source DB:  PubMed          Journal:  Best Pract Res Clin Anaesthesiol        ISSN: 1521-6896


  7 in total

Review 1.  Methadone for treatment of cancer pain.

Authors:  John Bryson; Anoo Tamber; Dori Seccareccia; Camilla Zimmermann
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

Review 2.  Intrathecal analgesia for refractory cancer pain.

Authors:  Scott Newsome; Bridget K Frawley; Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2008-08

Review 3.  Neuraxial pain relief for intractable cancer pain.

Authors:  Paul A Sloan
Journal:  Curr Pain Headache Rep       Date:  2007-08

4.  Morphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effects.

Authors:  Laura S Stone; Jonathan P German; Kelly F Kitto; Carolyn A Fairbanks; George L Wilcox
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

5.  Bupivacaine administered intrathecally versus rectally in the management of intractable rectal cancer pain in palliative care.

Authors:  Iwona Zaporowska-Stachowiak; Grzegorz Kowalski; Jacek Luczak; Katarzyna Kosicka; Aleksandra Kotlinska-Lemieszek; Maciej Sopata; Franciszek Główka
Journal:  Onco Targets Ther       Date:  2014-10-06       Impact factor: 4.147

6.  Survey of pain specialists regarding conversion of high-dose intravenous to neuraxial opioids.

Authors:  Andrew W Gorlin; David M Rosenfeld; Jillian Maloney; Christopher S Wie; Johnathan McGarvey; Terrence L Trentman
Journal:  J Pain Res       Date:  2016-09-21       Impact factor: 3.133

7.  Current aproach to cancer pain management: Availability and implications of different treatment options.

Authors:  Hrachya Nersesyan; Konstantin V Slavin
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.